
AMCP Market Insights: Webinar on ER+/HER2- Metastatic Breast Cancer Part 1
Overview
Tuesday, April 29, 2025 at 2-3pm ET Pricing: Free for Members and Non-Members
Please note that this session is not accredited for continuing pharmacy education credit.
Program Description
Join us for a webinar on ER+/HER2- Metastatic Breast Cancer, a disease affecting nearly 150,000 people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care.
This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in February 2025. Presenters will characterize the clinical and QOL burden of ER+/HER2, explore the mechanisms of action of current therapies, review current treatment options, describe therapeutics that targets ERs, and outline payer strategies to facilitate precision oncology care.
Learning Objectives
- Characterize the clinical and QOL burden of ER+/HER2- metastatic breast cancer.
- Explore the mechanisms of action of current therapies for ER+/HER2- metastatic breast cancer.
- Review the current treatment options for ER+/HER2- metastatic breast cancer and detail outcomes/survival associated with 2nd-line therapy.
- Describe therapeutics for metastatic breast cancer that target ERs, including PROTAC ER degraders.
- Outline payer strategies to facilitate precision oncology care for metastatic breast cancer with companion diagnostics.
Faculty
Speakers:
Laura Bobolts, PharmD, BCOP
SVP, Pharmacy
OncoHealth
Neal M. Iyengar, MD
Breast Medical Oncologist
Memorial Sloan Kettering
Alpha Lillstrom Cheng
Vice President
METAvivor
Register/Take course
Price
Required Hardware/software
AMCP Learn utilizes the Zoom Webinars platform for live webinars. For a smoother experience joining the webinar, please install the Zoom desktop client or mobile app prior to the start time. If you experience technical issues joining the webinar, please email webinars@amcp.org.